Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

Long-Term Non-Interventional Latanoprost Study (LYNX)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by Pfizer
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01265719
First received: December 16, 2010
Last updated: February 20, 2015
Last verified: February 2015
History of Changes
  Purpose

This is a non-interventional, prospective, longitudinal cohort study. A total of 150 pediatric subjects with glaucoma or elevated intraocular pressure, including 75 latanoprost-treated subjects and 75 non-topical prostaglandin analogue treated subjects, will be enrolled from ophthalmic hospital clinics and academic ophthalmic centers. As a non-interventional study, the study subjects' continued use of latanoprost and assessments of ocular events will be obtained through the routine medical follow-up with treating ophthalmologists or other designated members of the medical care team.


Condition Intervention Phase
Glaucoma
Ocular Hypertension
 Other: No intervention other than routine medical care
 Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective, Non-interventional, Longitudinal Cohort Study To Evaluate The Long-term Safety Of Latanoprost Treatment In Pediatric Populations.

Resource links provided by NLM:

Drug Information available for: Latanoprost
U.S. FDA Resources

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Best Corrected Visual Acuity (Snellen or equivalent) [ Time Frame: baseline ] [ Designated as safety issue: No ]
  • Best Corrected Visual Acuity (Snellen or equivalent) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Best Corrected Visual Acuity (Snellen or equivalent) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Best Corrected Visual Acuity (Snellen or equivalent) [ Time Frame: 24 months ] [ Designated as safety issue: No ]
  • Best Corrected Visual Acuity (Snellen or equivalent) [ Time Frame: 36 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Refractive error [ Time Frame: baseline ] [ Designated as safety issue: No ]
  • Refractive error [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Refractive error [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Refractive error [ Time Frame: 24 months ] [ Designated as safety issue: No ]
  • Refractive error [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Horizontal corneal diameter [ Time Frame: baseline ] [ Designated as safety issue: No ]
  • Horizontal corneal diameter [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Horizontal corneal diameter [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Horizontal corneal diameter [ Time Frame: 24 months ] [ Designated as safety issue: No ]
  • Horizontal corneal diameter [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Intraocular pressure [ Time Frame: baseline ] [ Designated as safety issue: No ]
  • Intraocular pressure [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Intraocular pressure [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Intraocular pressure [ Time Frame: 24 months ] [ Designated as safety issue: No ]
  • Intraocular pressure [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Optic nerve changes/structures [ Time Frame: baseline ] [ Designated as safety issue: No ]
  • Optic nerve changes/structures [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Optic nerve changes/structures [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Optic nerve changes/structures [ Time Frame: 24 months ] [ Designated as safety issue: No ]
  • Optic nerve changes/structures [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Visual field [ Time Frame: baseline ] [ Designated as safety issue: No ]
  • Visual field [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Visual field [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Visual field [ Time Frame: 24 months ] [ Designated as safety issue: No ]
  • Visual field [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Iris color darkening [ Time Frame: baseline ] [ Designated as safety issue: Yes ]
  • Iris color darkening [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • Iris color darkening [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Iris color darkening [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
  • Iris color darkening [ Time Frame: 36 months ] [ Designated as safety issue: Yes ]
  • Localized pigmentation (nevi or freckles) of conjunctiva, iris and choroid [ Time Frame: baseline ] [ Designated as safety issue: No ]
  • Localized pigmentation (nevi or freckles) of conjunctiva, iris and choroid [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Localized pigmentation (nevi or freckles) of conjunctiva, iris and choroid [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Localized pigmentation (nevi or freckles) of conjunctiva, iris and choroid [ Time Frame: 24 months ] [ Designated as safety issue: No ]
  • Localized pigmentation (nevi or freckles) of conjunctiva, iris and choroid [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Eyelash darkening/thickening [ Time Frame: baseline ] [ Designated as safety issue: Yes ]
  • Eyelash darkening/thickening [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • Eyelash darkening/thickening [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Eyelash darkening/thickening [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
  • Eyelash darkening/thickening [ Time Frame: 36 months ] [ Designated as safety issue: Yes ]
  • Length of eyelash [ Time Frame: baseline ] [ Designated as safety issue: Yes ]
  • Length of eyelash [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • Length of eyelash [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Length of eyelash [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
  • Length of eyelash [ Time Frame: 36 months ] [ Designated as safety issue: Yes ]
  • Corneal thickness [ Time Frame: baseline ] [ Designated as safety issue: No ]
  • Corneal thickness [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Corneal thickness [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Corneal thickness [ Time Frame: 24 months ] [ Designated as safety issue: No ]
  • Corneal thickness [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Conjunctiva hyperemia [ Time Frame: baseline ] [ Designated as safety issue: Yes ]
  • Conjunctiva hyperemia [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • Conjunctiva hyperemia [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Conjunctiva hyperemia [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
  • Conjunctiva hyperemia [ Time Frame: 36 months ] [ Designated as safety issue: Yes ]
Estimated Enrollment: 150
Study Start Date: December 2010
Estimated Study Completion Date: March 2016
Estimated Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Latanoprost-treatment group Other: No intervention other than routine medical care
Subjects continuously treated with Latanoprost for at least one month Latanoprost treatment during the study period.
Other Name: Observational
Non-topical prostaglandin analogue treatment group Other: No intervention other than routine medical care
Subjects not treated with any topical prostaglandin analogues or continuously treated with topical prostaglandin analogues for less than one month before the baseline examination, and unlikely to be treated with topical prostaglandin analogues during the study period.
Other Name: Observational

Detailed Description:

At least 40 subjects in each of the following age groups: 1-<5 years and 5-<18 years. No minimum required numbers in the <1 year age group.

  Eligibility
Ages Eligible for Study:   up to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Pediatric populations diagnosed with glaucoma or elevated intraocular pressure

Criteria

Inclusion Criteria:

  • Male or female <18 years of age (neonates must be at least 36 weeks gestational age).
  • Diagnosis of pediatric glaucoma or elevated intraocular pressure.
  • Evidence of a personally signed and dated informed consent document indicating that the subject (and/or a legally acceptable representative) has been informed of all pertinent aspects of the study. A signed and dated assent will be required where applicable according to local laws.

For treated subjects only:

  • Continuously treated with latanoprost for at least 1 month within the year prior to the baseline examination.

For untreated subjects only:

  • Continuously treated with latanoprost or other topical prostaglandin analogues for less than one month prior to the baseline examination (based on the best knowledge of treating ophthalmologists), and unlikely to be treated with latanoprost or other topical prostaglandin analogues during the three-year study period; OR
  • No prior treatment with latanoprost or other topical prostaglandin analogues, and unlikely to be treated with latanoprost or other topical prostaglandin analogues during the three-year study period.

Exclusion Criteria:

  • Unable/unwilling to comply with protocol.
  • Pregnant or nursing females at baseline.
  • For treated subjects only: a history of allergy or hypersensitivity to any of the ingredients contained in latanoprost (e.g., hypersensitivity to benzalkonium chloride).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01265719

Contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021

  Show 29 Study Locations
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
To obtain contact information for a study center near you, click here.  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01265719     History of Changes
Other Study ID Numbers: A6111143, LYNX
Study First Received: December 16, 2010
Last Updated: February 20, 2015
Health Authority: European Union: European Medicines Agency

Keywords provided by Pfizer:
Prospective
non-interventional
longitudinal
cohort study

Additional relevant MeSH terms:
Hypertension
Ocular Hypertension
Cardiovascular Diseases
Eye Diseases
Vascular Diseases
 Latanoprost
Antihypertensive Agents
Cardiovascular Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on February 25, 2015